Literature DB >> 8563750

Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia.

D A Largaespada1, C I Brannan, N A Jenkins, N G Copeland.   

Abstract

The Ras signal transduction pathway is often deregulated in human myeloid leukaemia. For example, activating point mutations in RAS genes are found in some patients with juvenile chronic myelogenous leukaemia (JCML), while other patients with JCML show loss of the neurofibromatosis type 1 (NF1) gene, a Ras GTPase activating protein. By generating mice whose haematopoietic system is reconsituted with Nf1 deficient haematopoietic stem cells we show that Nf1 gene loss, by itself, is sufficient to produce the myeloproliferative symptoms associated with human JCML. We also provide evidence to indicate that Nf1 gene loss induces myeloproliferative disease through a Ras-mediated hypersensitivity to granulocyte/macrophage-colony stimulating factor (GM-CSF). Finally, we describe a genetic screen for identifying genes that cooperate with Nf1 gene loss during progression to acute myeloid leukaemia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8563750     DOI: 10.1038/ng0296-137

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  70 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

3.  NF1 inactivation in adult acute myelogenous leukemia.

Authors:  Brian Parkin; Peter Ouillette; Yin Wang; Yan Liu; Whitney Wright; Diane Roulston; Anjali Purkayastha; Amanda Dressel; Judith Karp; Paula Bockenstedt; Ammar Al-Zoubi; Moshe Talpaz; Lisa Kujawski; Yang Liu; Kerby Shedden; Sajid Shakhan; Cheng Li; Harry Erba; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-05-26       Impact factor: 12.531

Review 4.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.

Authors:  Kelly J Morgan; Matthew A Rowley; Stephen M Wiesner; Diane E Hasz; Brian Van Ness; David A Largaespada
Journal:  Leuk Res       Date:  2007-01-12       Impact factor: 3.156

6.  Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.

Authors:  Rebecca J Chan; Todd Cooper; Christian P Kratz; Brian Weiss; Mignon L Loh
Journal:  Leuk Res       Date:  2008-10-26       Impact factor: 3.156

7.  Oncogenic Kras expression in postmitotic neurons leads to S100A8-S100A9 protein overexpression and gliosis.

Authors:  Myung-Jeom Ryu; Yangang Liu; Xiaofen Zhong; Juan Du; Nicholas Peterson; Guangyao Kong; Hongda Li; Jinyong Wang; Shahriar Salamat; Qiang Chang; Jing Zhang
Journal:  J Biol Chem       Date:  2012-05-10       Impact factor: 5.157

8.  Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.

Authors:  Steven D Rhodes; Hao Yang; Ruizhi Dong; Keshav Menon; Yongzheng He; Zhaomin Li; Shi Chen; Karl W Staser; Li Jiang; Xiaohua Wu; Xianlin Yang; Xianghong Peng; Khalid S Mohammad; Theresa A Guise; Mingjiang Xu; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2015-05-21       Impact factor: 6.741

9.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Authors:  Hideki Muramatsu; Hideki Makishima; Anna M Jankowska; Heather Cazzolli; Christine O'Keefe; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

10.  Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice.

Authors:  David Caudell; David P Harper; Rachel L Novak; Rachel M Pierce; Christopher Slape; Linda Wolff; Peter D Aplan
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.